Activists urge the Global Fund and donors to take prompt action to address the grave risks posed to countries that are rapidly shifting from pooled procurement of TB medicines and commodities.

Activists urge international donors and country governments to ensure access to quality health products as domestic financing policies push programs to the edge of procurement cliff.

In a symbolic display, activists invited conference participants to discard the injectable agents and commit to rapidly scaling up access to safer, more effective medicine.

Provocative distribution of yellow lemonade in urine collection cups calls attention to need for this simple, urine-based test.

Activists demand that Johnson & Johnson cut the price of bedaquiline in half, to no higher than $1 per day—$32 per person per month—double the price that researchers estimate bedaquiline could be sold for a profit.

Warns high prices of TB drugs restrict people's access to best drug-resistant TB treatment.

A new checklist from Treatment Action Group lays out simply the core elements of an adequate TB response.

The "Reality Check" dispels myths that have been circulated among members of the global TB community and used to justify pricing bedaquiline out of the reach of TB programs and patients.

First-ever targeted roadmap outlines steps to scale-up public-private health sector engagement to end TB.

Advocates ask Otsuka to lower the price of delamanid in line with Médecins sans Frontières target regimen cost of $500.